The Antioxidative Barier in Patients with Colorectal Cancer

• Authors: Łukasz Murlikiewicz , Radzisław Trzciński , Andrzej Sygut , Maciej Rutkowski , Krzysztof Grzegorczyk , Adam Dziki
• Languages of publication: EN

Abstracts

EN

Colorectal cancer is still a major medical, economical and public health problem. Pathogenesis of colorectal cancer remains unknown. It is thought both genetic and environmental factors contribute to the etiology and progression of the disease. Reactive oxygen species are known to play a dual role in biological systems they can be either harmful or beneficial. Oxygen-free radicals are important mediators of damage to cell structures, including lipids, proteins and nucleic acids. Radical-related damage to cell structures has been proposed to play a key role in the development of many diseases including cancer.Humans have evolved complex antioxidant strategies to protect cells from oxidation.Total antioxidant capacity (TAC) considers the cumulative action of all the antioxidants present in plasma or other body fluids.The aim of the study was to investigate antioxidant status in patients with colorectal cancer measuring plasma TAC as a tool.Material and methods. The study group comprised 102 patients in different clinical stages operated on for colorectal cancer. To evaluate plasma total antioxidant capacity we used "Total Antioxidant Status Kit" - RandoxResults. Statistical evaluation of results demonstrated significantly lower serum total antioxidant capacity in patients with colorectal cancer, as compared to the healthy control group. We observed increase mean plasma total antioxidant capacity correlating with decrease of clinical disease stage.Conclusions. Colorectal patient have impairment antioxidant barrier. The deterioration of its functioning corresponds with the stage of the disease.

Keywords

EN

colorectal cancer; antioxidant barrier; oxygen-free radicals

• Publisher: Index Copernicus International
• Journal: Polish Journal of Surgery
• Year: 2010
• Volume: 82
• Issue: 6
• Pages: 341-346

Dates

published

1 - 6 - 2010

online

15 - 9 - 2010

Contributors

author

Łukasz Murlikiewicz

• Department of General and Colorectal Surgery, Medical University in Łódź

author

Radzisław Trzciński

• Department of General and Colorectal Surgery, Medical University in Łódź

author

Andrzej Sygut

• Department of General and Colorectal Surgery, Medical University in Łódź

author

Maciej Rutkowski

• Department of Clinical Biochemistry, Medical University in Łódź

author

Krzysztof Grzegorczyk

• Department of Endoscopy and Department of One-day Gastroenterology, Wł. Biegański Memorial Voivodship Specialistic Hospital in Łódź

author

Adam Dziki

• Department of General and Colorectal Surgery, Medical University in Łódź

References

• Didkowska J, Wojciechowska U, Tarkowski W i in.: Nowotwory złośliwe w Polsce w 2005 roku. Biuletyn Centrum Onkologii w Warszawie. Warszawa 2007.
• Nelson H, Petrelli N, Carlin A et al.: Guidelines 2000 for Colon and Rectal Cancer Surgery. J Natl Cancer Inst 2001; 93: 583-96.[Crossref]
• Finn OJ: Cancer immunology. Molecular origins of cancer. N Engl J Med 2008; 358: 2704-19.[Crossref]
• Walsh JME, Terdiman JP: Colorectal cancer screening: scientific review. JAMA 2003; 289: 1288-98.[Crossref][PubMed]
• Fernandez E, Negr E, La Vecchia C et al.: Diet diversity and colorectal cancer. Prev Med 2000; 31: 11-14.[Crossref]
• Leslie A, Carey FA, Pratt NR: The colorectal adenoma-carcinoma sequence Br J Surg 2002; 89: 845-60.[PubMed]
• Guillem JG, Smith AJ, Puig-La Calle J et al.: Gastrointestinal polyposis syndromes. Curr Probl Surg 1999; 36: 219-23.
• Łuszczewski A, Matyska-Piekarska E, Trefler J i wsp.: Reaktywne formy tlenu - znaczenie w fizjologii i stanach patologii organizmu. Reumatologia 2007; 45: 284-89.
• Skrzycki M, Czeczot H: Rola dysmutazy ponadtlenkowej w powstawaniu nowotworów. Postępy Nauk Med 2005; 4: 7-15.
• Ponczek MB, Wachowicz B: Oddziaływanie reaktywnych form tlenu i azotu z białkami. Postępy Biochem 2005; 51: 140-45.
• Cejas P, Casado E, Belda-Iniesta C et al.: Implications of oxidative stress and cell membrane lipid peroxidation in human cancer. Cancer Causes Control 2004;15: 707-19.[Crossref]
• Barrera G, Pizzimenti S, Dianzani MU: Lipid peroxidation: control of cell proliferation, cell differentiation and cell death. Mol Aspects Med 2008; 29: 1-8.[PubMed][WoS][Crossref]
• Skrzydlewska E, Stankiewicz A, Sułkowska M et al.: Antioxidant status and lipid peroxidation in colorectal cancer. J Toxicol Environ Health 2001; 64: 213-22.[Crossref]
• Błauż A, Pilaszek T, Grzelak A et al.: Interaction between antioxidants in assays of total antioxidant capacity. Food Chem Toxicol 2008; 46: 2365-68.[WoS][Crossref]
• Liu J, Zhang X, Yang F et al.: Antimetastatic effect of a lipophilic ascorbic acid derivative with antioxidation through inhibition of tumor invasion. Cancer Chemother Pharmacol 2006; 57: 584-90.[Crossref]
• Miller NJ, Rice-Evans C, Davies MJ et al.: A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407-12.[PubMed]
• Plavec T, Nemec SA, Butinar J et al.: Antioxidant status in canine cancer patients. Acta Vet 2008; 58: 275-86.[WoS]
• Hietanen E, Bartsch H, Béréziat JC et al.: Diet and oxidative stress in breast, colon and prostate cancer patients: a case-control study. Eur J Clin Nutr 1994; 48: 575-86.
• Erhola M, Nieminen MM, Kellokumpu-Lehtinen J et al.: Effects of surgical removal of lung cancer on total plasma antioxidant capacity in lung cancer patients. J Exp Clin Cancer Res 1998; 17: 219-25.
• Skrzydlewska E, Stankiewicz A, Michalak K et al.: Antioxidant status and proteolytic-antiproteolytic balance in colorectal cancer. Folia Histochem Cytobiol 39(Suppl.2): 98-99.
• Czeczot H, Skrzycki M, Podsiad M i wsp.: Potencjał antyoksydacyjny u chorych na pierwotnego raka jelita grubego oraz z przerzutami z raka jelita grubego do wątroby. Pol Merkuriusz Lek 2005; 18: 58-61.
• Kim SY, Ko JW, Koo JE et al.: Changes in lipid peroxidation and antioxidant trace elements in serum of women with cervical intraepithelial neoplasia and invasive cancer. Nutr Cancer 2003; 47: 126-30.[Crossref]
• Czeczot H, Skrzycki M, Gawryszewska E i wsp.: Ocena statusu antyoksydacyjnego u chorych z pierwotnym rakiem wątroby. Pol Merkur Lekarski 2003; 15: 118-22.
• Balcerska A, Stachowicz-Stencel T, Łysiak-Szydłowska W: Dynamika przebiegu choroby nowotworowej a stan bariery antyoksydacyjnej ustroju. Wiad Lek 2000; 53: 128-33.
• Mantovani G, Macciò A, Madeddu C et al.: Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer 2002; 98: 84-91.[Crossref]
• Dęgowska M, Rydzewska G: Chemoprewencja raka jelita grubego - rola mesalazyny Przegl Gastroenterol 2008; 5: 247-54.
• Levine RL: Carbonyl modified proteins in cellular regulation, aging and disease. Free Radic Biol Med 2002; 32: 790-96.[Crossref]
• Blot WJ, Li JY, Taylor PR et al.: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483-92.[Crossref]
• National Cancer Institute -

Identifiers

DOI

10.2478/v10035-010-0049-2